PEVIA Consortium Submits 1st Intermediate Report
01
AUG

PEVIA Consortium Submits 1st Intermediate Report

Learn more...

By vaxeal Team
EUROPEAN BIOPHARMACEUTICAL ENTERPRISES ANNOUNCES CEO OF VAXEAL AS NEW PRESIDENT
02
JUL

EUROPEAN BIOPHARMACEUTICAL ENTERPRISES ANNOUNCES CEO OF VAXEAL AS NEW PRESIDENT

Learn more...

By vaxeal Team
AHMED BOUZIDI GAVE A PRESENTATION AT THE INTERPAT GENERAL ASSEMBLY
20
JUN

AHMED BOUZIDI GAVE A PRESENTATION AT THE INTERPAT GENERAL ASSEMBLY

Learn more...

By vaxeal Team
GEOVAX AND VAXEAL COLLABORATE ON CANCER IMMUNOTHERAPY PROGRAM
03
JAN

GEOVAX AND VAXEAL COLLABORATE ON CANCER IMMUNOTHERAPY PROGRAM

Learn more...

By vaxeal Team
The IMI-funded PEVIA Project Officially Kicked-off
05
OCT

The IMI-funded PEVIA Project Officially Kicked-off

Learn more...

By vaxeal Team
PEVIA consortium created by VAXEAL has received a grant of 6.2M€ from the Innovative Medicines Initiative (IMI)
01
JUN

PEVIA consortium created by VAXEAL has received a grant of 6.2M€ from the Innovative Medicines Initiative (IMI)

Learn more...

By vaxeal Team
AHMED BOUZIDI, PANELIST AT THE 4th ANNUAL EAPM PRESIDENCY CONFERENCE
16
APR

AHMED BOUZIDI, PANELIST AT THE 4th ANNUAL EAPM PRESIDENCY CONFERENCE

Learn more...

By vaxeal Team
VAXEAL PARTICIPATED IN THE IPROVE ROADMAP
28
MAR

VAXEAL PARTICIPATED IN THE IPROVE ROADMAP

Learn more...

By vaxeal Team
THE MEMBERS OF THE ANR-13-RPIB-0004 CONSORTIUM SUBMITTED THE FIRST INTERMEDIATE REPORT ON SVX-1
12
DEC

THE MEMBERS OF THE ANR-13-RPIB-0004 CONSORTIUM SUBMITTED THE FIRST INTERMEDIATE REPORT ON SVX-1

Learn more...

By vaxeal Team